Allergy Thera. Regulatory News (AGY)

30 September 2010

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Board Changes

In line with the plans announced in its preliminary results statement on 20 September 2010, Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has reduced the size of the Board and changed its composition to ensure there is a majority of independent non-executive directors.

Peter Jensen has been appointed as a Non-executive Director with immediate effect. Peter will become Non-executive Chairman on 1 January 2011, replacing Ignace Goethals who will step down from that role but will remain on the Board as a Non-executive Director.

In addition, Tom Holdich and Christian Grätz have resigned from the Board and Keith Carter will resign with effect from 31 December 2010. However, both Tom and Christian will remain with the Company and continue their executive management positions. Following these changes the Board will comprise two Executive Directors and five Non-executive Directors.

Peter spent 20 years with SmithKlineBeecham Plc working in a variety of senior management positions including the role of President of Worldwide Supply Operations and Chairman of Consumer Healthcare Europe, as well as several senior marketing roles. Peter headed the executive team that helped to create GlaxoSmithKline as Europe's leading consumer healthcare business. In the last five years, Peter has held non-executive directorships with Genetix Group Plc, Celsis International Plc and a number of companies outside of the healthcare sector.

Ignace Goethals, Chairman of Allergy Therapeutics, said:

"We are delighted to welcome Peter to the Board and are extremely pleased that he will become Allergy's Chairman in January. Peter brings extensive industry and board experience which will be invaluable to the Company as it delivers on plans to grow the business.

"I would like to thank Keith for his commitment and immense contribution to the Company over many years both as a director and for several years as CEO. We wish him every success for the future."

Additional information regarding Peter Jensen

Peter Sinclair Jensen aged 59 has the following appointments as a director or partner:

·; In June 2010 Inion OY entered into voluntary liquidation

There are no further disclosures required under Schedule 2 paragraph (g) of the AIM rules

For further information